Five leading MASLD patient advocates discuss their initial reactions when Rezdiffra became the first MASH drug approved in the US on March 14.
Last Thursday, March 14, Rezdiffra (resmetirom) became the first drug approved in the US for MASH. Five leading North American MASLD patient advocates join the Surfers to discuss their feelings about this approval along with the opportunities and challenges that lie ahead.
This conversation focuses on what panelists believe to be the major lessons the BioPharma industry should take from Madrigal’s success in bring Rezdiffra to launch.
The launch of Rezdiffra raises this pivotal question: which MASH patients are the correct initial targets for the first MASH drug?
As panelists ponder practical issues about when and to whom to prescribe Rezdiffra, they consider the benefits and shortcomings of existing NITs.
SurfingMASH’s coverage of the Rezdiffra approval shifts to a seemingly tangential topic: impact of drug approval on patient adherence with lifestyle recommendations.
Key Opinion Leaders for Europe and the US join the Surfers the day after the first MASH drug, Rezdiffra, was approved, to discuss how they heard the news and what kinds of patients they envision as initial targets.
Last Thursday, FDA approved Rezdiffra, the first MASH drug! A global panel of key opinion leaders joins the Surfers to share excitement and discuss the implications of this landmark event.
This final conversation focuses on semaglutide and some of the dual- and triple-increting agonists and then reviews high points of the entire episode.
This conversation includes two separate themes: the rationale and impact around the price of resmetirom, and the impact of GLP-1s on resmetirom use in patients with MASH.
